A Phase II, Opened, Not Controlled and Multicentric Clinical Trial of Pazopanib in Monotherapy to Determine Efficiency and Safety in Second-line of Treatment in Patients With Carcinoma of Advanced Renal Cells That Have Progressed or Have Not Tolerated the First Line of Treatment With Tyrosine Kinase Inhibitor
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2016
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 22 Nov 2016 Status changed from active, no longer recruiting to completed.
- 28 Jun 2012 New source identified: European Clinical Trials Database record (EudraCT2011-002441-34) integrated.
- 23 Apr 2012 New trial record